การใช้สารกัมมันตรังสีใน การรักษาความเจ็บปวดจาก มะเร็งแพร่กระจายมาที่กระดูก
References
Ahonen A, Joensuu H, Hiltunen J, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994;38: 123-127.
Baxiotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998;55: 377-381.
Blitzer PH, Dosoretz DE, Floody PA, et al. Strontium-89 chloride in the palliation of bone pain from metastatic cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14:505-512.
Chen S, Xu K, Liu W, et al. Treatment of metastatic bone pain with rhenium-188 hydroxyethylidene diphosphonate, Med Principles Pract 2001;10:98-101.
Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34: 1839-1844.
Defermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28: 788-798.
Dearnaley DP, Bayly RJ, A'Hern RP, et al. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89, Clin Oncol 1992;4:101-107.
Deng HF, Luo SZ, Tan TZ, et al. The effect of 153-Sm-EDTMP on moderate and severe bone cancer pain [abstract]. J Nucl Med 1997;38:251P.
Han SH, Zonnenberg BA, Quirijnen JMSP, et al. Efficacy of rhenium-186-etidronate in breast cancer patients with metastatic bone pain [abstract].Eur J Nuc Med 1997;24:895.
Kasalicky J, Krajska V. The effect of repeated strontium-89chioride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25:1362-1367.
Kasalicky J, Krajska V, Broz J, Kopacek R, Nestaval A. The effect of 153Sm-EDTMP on painful bone metastases; comparison with 89 SrCl [abstract]. Eur J Nucl Med 1996:23.
Kucuk NO, Ibis E, Aras G, et al. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases, Ann Nucl Med 2000;14: 239-245.
Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-822.
Lamki LM, Haynie TP, Dexeus F, et al. Strontium-89 (Sr-89) in the palliative therapy of painful bone metastases: a phase II clinical study [abstract]. J Nucl Med 1989;30:836.
Maxon III HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases results of a double -blind crossover comparison with placebo. J Nucl Med 1991;32:1877-1881.
McEwan AJB, Amyotte G, MacLean GD, et al. Strontium-89 to treat patients with breast cancer metastatic to bone [abstract]. Eur J Nucl Med 1994;21:S44.
Olea E, Riccabona G, Tian J, et al.Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study [abstract]. J Nucl Med 2000;51:146P.
Palmedo H, Albers P, Guhlke S, et al. 188Re HEDP in the treatment of bone metastases generating from prostate cancer [abstract]. J Nucl Med 2002;43: 160P.
Porter AT, McEwan AJ, strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol 1993;20:38-43.
Reddy EK, Robinson RG, Mansfield CM. Strontium-89 for palliation of bone metastases. J Natl Med Assoc 1986;78: 27-32.
Sartor O. Overview of Samarium Sm153 Lexidronam in the Treatment of Painful Metastatic Bone Disease. Rev Urol 2004;6(Suppl 10):S3-S12.
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 iexidronam : a double-blind placebocontrolled clinical trial. J Clin Oncol 1998; 16:1574-1581.
Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate : a randomised phase II trial. Lancet 2001;357:336-341.
Tu SM, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 1996;2:191-197.
Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol 2001;13:219-227.
Baxiotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998;55: 377-381.
Blitzer PH, Dosoretz DE, Floody PA, et al. Strontium-89 chloride in the palliation of bone pain from metastatic cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14:505-512.
Chen S, Xu K, Liu W, et al. Treatment of metastatic bone pain with rhenium-188 hydroxyethylidene diphosphonate, Med Principles Pract 2001;10:98-101.
Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34: 1839-1844.
Defermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001;28: 788-798.
Dearnaley DP, Bayly RJ, A'Hern RP, et al. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89, Clin Oncol 1992;4:101-107.
Deng HF, Luo SZ, Tan TZ, et al. The effect of 153-Sm-EDTMP on moderate and severe bone cancer pain [abstract]. J Nucl Med 1997;38:251P.
Han SH, Zonnenberg BA, Quirijnen JMSP, et al. Efficacy of rhenium-186-etidronate in breast cancer patients with metastatic bone pain [abstract].Eur J Nuc Med 1997;24:895.
Kasalicky J, Krajska V. The effect of repeated strontium-89chioride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25:1362-1367.
Kasalicky J, Krajska V, Broz J, Kopacek R, Nestaval A. The effect of 153Sm-EDTMP on painful bone metastases; comparison with 89 SrCl [abstract]. Eur J Nucl Med 1996:23.
Kucuk NO, Ibis E, Aras G, et al. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases, Ann Nucl Med 2000;14: 239-245.
Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-822.
Lamki LM, Haynie TP, Dexeus F, et al. Strontium-89 (Sr-89) in the palliative therapy of painful bone metastases: a phase II clinical study [abstract]. J Nucl Med 1989;30:836.
Maxon III HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases results of a double -blind crossover comparison with placebo. J Nucl Med 1991;32:1877-1881.
McEwan AJB, Amyotte G, MacLean GD, et al. Strontium-89 to treat patients with breast cancer metastatic to bone [abstract]. Eur J Nucl Med 1994;21:S44.
Olea E, Riccabona G, Tian J, et al.Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study [abstract]. J Nucl Med 2000;51:146P.
Palmedo H, Albers P, Guhlke S, et al. 188Re HEDP in the treatment of bone metastases generating from prostate cancer [abstract]. J Nucl Med 2002;43: 160P.
Porter AT, McEwan AJ, strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol 1993;20:38-43.
Reddy EK, Robinson RG, Mansfield CM. Strontium-89 for palliation of bone metastases. J Natl Med Assoc 1986;78: 27-32.
Sartor O. Overview of Samarium Sm153 Lexidronam in the Treatment of Painful Metastatic Bone Disease. Rev Urol 2004;6(Suppl 10):S3-S12.
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 iexidronam : a double-blind placebocontrolled clinical trial. J Clin Oncol 1998; 16:1574-1581.
Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate : a randomised phase II trial. Lancet 2001;357:336-341.
Tu SM, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 1996;2:191-197.
Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol 2001;13:219-227.
Downloads
Published
2008-06-30
How to Cite
1.
สุขถมยา ว. การใช้สารกัมมันตรังสีใน การรักษาความเจ็บปวดจาก มะเร็งแพร่กระจายมาที่กระดูก. J Thai Assn of Radiat Oncol [Internet]. 2008 Jun. 30 [cited 2024 May 19];14(1):53-60. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203562
Issue
Section
Original articles
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
